fty720  (Merck & Co)

Journal: The Journal of Immunology Author Choice

Article Title: Effectiveness and immunogenicity of a nanoemulsion protein subunit vaccine against Pseudomonas aeruginosa : investigation in diet-induced obese mice

doi: 10.1093/jimmun/vkag052

Figure Lengend Snippet: FTY720 treatment distinguishes circulating from lung-resident CD4 + T-cell populations following L-PaF/ME/BECC immunization. Lung tissues were harvested 56 days post–initial immunization following Pseudomonas aeruginosa (Pa) infection to assess the presence of tissue-resident memory cells through flow cytometric analysis without or with FTY720 treatment. (A, B) CD3 + CD4 + T cells in HFD and LFD mice without or with FTY720 treatment. (C, D) Frequency of CD44 low CD62L high naïve CD4 + T cells in the lungs of PBS- and L-PaF/ME/BECC-immunized mice, without or with FTY720. (E, F) Frequency of CD44 high CD62L low effector/memory CD4 + T cells in immunized vs control groups under FTY720 treatment. (G, H) Frequency of CD69 + CD103 + tissue-resident memory (Trm) CD4 + T cells within the CD44 high CD62L low subset in immunized and PBS-treated mice across both diet cohorts. (I, J) Lung burdens following Pa challenge in immunized and control mice without or with FTY720 treatment. Each data point represents an individual mouse ( n = 4 or 5). Error bars represent SD. Statistical comparisons were performed using 2-way ANOVA following uncorrected Fisher least significant difference test (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001). All of the dot plots are in .

Article Snippet: Mice received intraperitoneal injections of FTY720 (Tocris Bioscience, cat # 6176) (1 mg/kg) or PBS as indicated beginning 3 days prior to infection.

Techniques: Infection, Control

Journal: eBioMedicine

Article Title: Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in preclinical mouse models

doi: 10.1016/j.ebiom.2026.106137

Figure Lengend Snippet: Inhibition of the abscopal effect of the MIMIC combination therapy on peritoneal dissemination by FTY720 treatment . (A, B) Overview (A) and protocol (B) for treatment with MIMIC and FTY720 in the FC1245 model. MIMIC: the combination of oxaliplatin, anti-PD-1 antibody, anti-CTLA-4 antibody, and IFNα/IL12-mRNA. Ox: oxaliplatin. ICI: immune checkpoint inhibitors consisting of anti-PD-1 antibody and anti-CTLA-4 antibody. mRNA: IFNα/IL12-mRNA. s.c.: subcutaneous injection. i.p.: intraperitoneal injection. (C) Subcutaneous tumour volumes (Control, n = 4; MIMIC, n = 6; MIMIC + FTY720, n = 6). P-values were calculated by ANOVA with the Tukey–Kramer post hoc test. (D) Representative photo images of peritoneal dissemination. (E – G) Numbers (E) , volumes (F) , and total weights (G) of peritoneal tumours. P-values were calculated by ANOVA with the Tukey–Kramer post hoc test. (H) Representative flow cytometry plots of CD8+ CD44+ CD62L− effector memory T (Tem) cells. (I–K) Quantification of lymphocytes (I) , CD8+ T cells (J) , and CD8+ CD44+ CD62L− Tem cells (K) in peripheral blood. P-values were calculated by ANOVA with the Tukey–Kramer post hoc test. (L) Representative immunohistochemical images of CD11c+ DCs in subcutaneous and peritoneal tumour tissues. The scale bar represents 100 μm. (M, N) Numbers per field of CD11c-positive cells in subcutaneous (M) and peritoneal (N) tumour tissues. P-values were calculated by ANOVA with the Tukey–Kramer post hoc test. (O) Representative immunohistochemical images of CD8+ T cells in subcutaneous and peritoneal tumour tissues. The scale bar represents 100 μm. (P, Q) Numbers per field of CD8-positive cells in subcutaneous (P) and peritoneal (Q) tumour tissues. P-values were calculated by ANOVA with the Tukey–Kramer post hoc test. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.

Article Snippet: Oral treatment of FTY720 (Tokyo Chemical Industry) was performed at 25 μg/head on Day 3, followed by 5 μg/head daily, as previously described.

Techniques: Inhibition, Injection, Control, Flow Cytometry, Immunohistochemical staining